FBR & Co Research Analysts Raise Earnings Estimates for Conatus Pharmaceuticals Inc. (CNAT)
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Analysts at FBR & Co increased their FY2016 EPS estimates for shares of Conatus Pharmaceuticals in a report released on Thursday. FBR & Co analyst V. Bernardino now expects that the firm will post earnings of ($1.29) per share for the year, up from their prior estimate of ($1.31). FBR & Co currently has a “Outperform” rating and a $16.00 price objective on the stock. FBR & Co also issued estimates for Conatus Pharmaceuticals’ Q4 2016 earnings at ($0.33) EPS, FY2017 earnings at ($0.66) EPS and FY2018 earnings at ($0.53) EPS.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Tuesday, November 8th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.03. During the same period in the previous year, the firm posted ($0.31) earnings per share.
Several other equities research analysts have also recently weighed in on the company. Brean Capital reissued a “buy” rating and set a $7.00 price objective on shares of Conatus Pharmaceuticals in a research note on Tuesday, October 4th. Zacks Investment Research raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Wednesday, August 10th. JMP Securities reissued a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Wednesday, November 9th. Finally, Stifel Nicolaus reduced their price objective on Conatus Pharmaceuticals from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $8.54.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 2.00 on Monday. Conatus Pharmaceuticals has a 1-year low of $1.40 and a 1-year high of $4.05. The stock has a 50 day moving average price of $1.89 and a 200-day moving average price of $2.05. The stock’s market cap is $44.14 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Courage Capital Management LLC acquired a new position in Conatus Pharmaceuticals during the third quarter worth approximately $200,000. KCG Holdings Inc. acquired a new position in Conatus Pharmaceuticals during the third quarter worth approximately $135,000. D. E. Shaw & Co. Inc. boosted its position in Conatus Pharmaceuticals by 94.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 87,788 shares of the biotechnology company’s stock worth $175,000 after buying an additional 42,649 shares in the last quarter. Vanguard Group Inc. boosted its position in Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares in the last quarter. Finally, AXA boosted its position in Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock worth $2,237,000 after buying an additional 14,939 shares in the last quarter. 22.89% of the stock is currently owned by hedge funds and other institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.